2025-05-27

New progress in Jiuzhitang Maker's clinical trial for stem cell therapy of pulmonary alveolar proteinosis draws attention.

The road ahead is long and arduous, but Jiuzhitang Maker fully understands that stem-cell drug development still faces numerous challenges. Yet, the company will seize this forum as a pivotal opportunity to reaffirm its confidence, ramp up R&D investments, continuously optimize resource integration, and strengthen collaborative partnerships. Together, we’ll accelerate the translation of groundbreaking stem-cell research into tangible clinical applications, bringing patients with pulmonary alveolar proteinosis more treatment options and renewed hope—and ultimately contributing significantly to the growth of the stem-cell pharmaceutical industry.

2025-04-16

Jiuzhitang Maker makes its debut at the 2025 Wuzhen Health Conference, paving the way for innovative advancements in the stem cell field.

This year's conference, themed "Towards Spring: Internal and External Drivers Amidst Transformation," brought together the leading players of China's health industry ecosystem, creating a remarkable annual showcase of the pharmaceutical and healthcare sectors. As a standout in the stem-cell field, Jiuzhitang Maker demonstrated its exceptional expertise at the event, highlighting the vibrant spirit of innovation and heritage that has long defined the time-honored pharmaceutical brand, Jiuzhi堂. This performance not only injected fresh energy into the industry but also sparked meaningful reflection on its future trajectory.

2025-04-02

Common Challenges in Stem Cell Drug Development and Industrialization — The CMC Pharmaceutical Perspective

As the inaugural article in our series on stem cell-based drug development, this piece will focus on the key milestones in stem cell drug research and innovation. Our aim is to spark discussion and inspire practitioners by offering practical insights and guidance, ultimately working together to accelerate the advancement of stem cell drug development and its commercialization.

2025-01-02

Mesoblast's Lesson: Can Chinese Stem-Cell Companies Rise to the Challenge?

Jiuzhitang Maker aims to leverage its CQDMO service platform to provide stem cell companies not only with GMP-compliant facilities, a dedicated team of experts, and a robust quality management system that meets both Chinese and U.S. regulatory requirements, but also with expert guidance rooted in its own extensive experience—ranging from developing tailored production strategies and refining quality-control methodologies to preparing comprehensive registration dossiers. Together with industry peers, Jiuzhitang Maker is committed to advancing collaboration, fostering mutual success, and collectively driving the growth and innovation of China’s stem cell sector.

2024-11-27

The kickoff meeting for the Jiuzhitang MakerWMS system project was successfully held.

In his concluding remarks, Zhang Quancheng, Chairman of Jiuzhitang Maker, emphasized that this project is of great significance, set to profoundly impact Meike's digital transformation, quality management system, and overall enterprise governance, while also accelerating the digitalization process across the entire Jiuzhitang ecosystem. He urged both teams to adhere rigorously to the planned timeline, ensure meticulous implementation, enhance operational efficiency, and guarantee the project’s practicality—while simultaneously laying a solid foundation for future initiatives, such as the construction of Phase II facilities.

2024-10-22

Warmly celebrating Jiuzhitang Maker for winning the Grand Prize at the Tsinghua Alumni Global Finals in Health and Medical Innovation!

Jiuzhitang Maker’s “Mesenchymal Stem Cell Drug Development Project” advanced through multiple rounds of competition in the regional qualifiers and successfully earned a spot in this year’s global finals. Standing out with its cutting-edge, innovative technology, the project was awarded the Champion Prize in the Angel Growth Category.

2024-04-29

Jiuzhitang Maker Supports the Successful Concluding of the Cell Therapy Drug R&D and Regulatory Submission Seminar

The successful convening of this conference comes at a pivotal moment as China continues to deepen its pharmaceutical regulatory reforms, cell therapy products have received approval for market launch, clinical trials for stem-cell-based drugs are in full swing, and numerous companies are actively preparing to submit applications for innovative cell therapies. This milestone underscores Jiuzhitang Maker's position as a leading player in the cell therapy industry, leveraging its exceptional technological expertise, extensive practical experience, and commitment to open collaboration—qualities that are now driving forward the research, development, and regulatory submissions of cell-based medicines in China. In doing so, Jiuzhitang Maker is making significant contributions toward building a healthy, well-organized, and innovation-driven ecosystem for cell therapy. Looking ahead, Jiuzhitang Maker remains steadfast in its mission, partnering closely with industry peers to jointly usher in a new chapter for China’s cell therapy sector.

2024-04-08

Jiuzhitang Maker's Quality Control Department has been awarded the accreditation certificate by the China National Accreditation Service for Conformity Assessment (CNAS).

Recently, Jiuzhitang Maker (Beijing) Cell Technology Co., Ltd. (hereinafter referred to as "Jiuzhitang Maker") announced exciting news: after a rigorous professional evaluation, the company's Quality Control Department has successfully obtained the accreditation certificate (registration number CNAS L20479) issued by the China National Accreditation Service for Conformity Assessment (CNAS).

2024-03-22

You're invited to the Seminar on Cell-Based Drug Development and Regulatory Submission

The Cell Drug R&D and Regulatory Submission Workshop, hosted by the China Association for Medical Biotechnology and co-organized by Jiuzhitang Maker (Beijing) Cell Technology Co., Ltd., will be officially held in Beijing on April 25–26, 2024. The workshop will feature industry experts who will share insights into the development journey and regulatory pathways for bringing cell therapy products to market—providing invaluable guidance to help more cell therapy companies enhance their drug-approval capabilities and boost success rates, ultimately driving the efficient and standardized growth of the cell therapy industry.